Highlights

January 06, 2022 12:05 PM Eastern Standard Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today

November 30, 2021 02:01 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced the opening

- Potential to bring in-house cell-based therapies that potentiate checkpoint inhibitors November 23, 2021 06:41 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”) a privately held clinical-stage biotechnology

November 18, 2021  ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (‘ITI’), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced that Kristen Batich, MD, Ph.D.

July 27, 2021 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today

July 21, 2021 10:35 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today

Biotech leader joins team as company evolves investigational UNITE platform and advances business July 19, 2021 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical

April 27, 2021 12:00 UTC ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually May 4-6, 2021.

Partnership Leverages Lineage’s Investigational VAC Allogeneic Cancer Vaccine Platform and Immunomic’s Proprietary Tumor Associated Antigen to Generate a Novel Oncology Product Candidate ROCKVILLE, Md. & CARLSBAD, Calif.--(BUSINESS WIRE)-- Immunomic Therapeutics,

December 01, 2020 08:05 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI) announced today that it will be presenting at the 2nd Annual Glioblastoma Drug Development Virtual Summit.

November 19, 2020 04:05 PM Eastern Standard Time ROCKVILLE, Md. & DURHAM, N.C.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms,

10 International Vaccine Influencers Who Exemplify Maryland’s Leading Role in Public Health Immunomic Therapeutics is listed as one of the Top 10 Maryland Vaccine Influencers in public health and Dr.